Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 166 to 180 of 390 results for ultrasound

  1. Radiofrequency ablation for atrial fibrillation in association with other cardiac surgery (HTG72)

    Evidence-based recommendations on radiofrequency ablation for atrial fibrillation in association with other cardiac surgery. This involves scarring the heart tissue using heat to interrupt abnormal electrical signals.

    HealthTech guidance
    Published
    25 May 2005
    View recommendations

    Sections for HTG72

  2. PulmoVista 500 for monitoring ventilation in critical care (MIB203)

    NICE has developed a medtech innovation briefing (MIB) on PulmoVista 500 for monitoring ventilation in critical care .

    Medtech innovation briefing
    Published
    17 December 2019

  3. superDimension Navigation System to help diagnostic sampling of peripheral lung lesions (MIB194)

    NICE has developed a medtech innovation briefing (MIB) on superDimension Navigation System to help diagnostic sampling of peripheral lung lesions .

    Medtech innovation briefing
    Published
    11 October 2019

  4. Hysteroscopic metroplasty of a uterine septum for recurrent miscarriage (HTG364)

    Evidence-based recommendations on hysteroscopic metroplasty of a uterine septum for recurrent miscarriage. This involves removing the septum using instruments passed through a thin tube with a camera inserted into the womb.

    HealthTech guidance
    Published
    23 January 2015
    View recommendations

    Sections for HTG364

  5. Injectable bulking agents for faecal incontinence (HTG135)

    Evidence-based recommendations on injectable bulking agents for faecal incontinence. This involves injecting a material into the muscles around the anus to bulk the sides of the sphincter.

    HealthTech guidance
    Published
    28 February 2007
    View recommendations

    Sections for HTG135

  6. Microwave ablation for atrial fibrillation in association with other cardiac surgery (HTG73)

    Evidence-based recommendations on microwave ablation for atrial fibrillation in association with other cardiac surgery. This involves scarring the heart tissue using heat produced from microwave energy to interrupt abnormal electrical signals.

    HealthTech guidance
    Published
    25 May 2005
    View recommendations

    Sections for HTG73

  7. Obinutuzumab for treating serologically active extra-renal lupus [ID6670]

    In development Reference number: GID-TA11886 Expected publication date:  13 May 2027

    Technology appraisal guidance
    In development

  8. MiraQ for assessing graft flow during coronary artery bypass graft surgery (HTG275)

    Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery.

    HealthTech guidance
    Last updated
    5 July 2022
    View recommendations

    Sections for HTG275

  9. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

    NICE guideline
    Last updated
    14 April 2025
    View recommendations

    Sections for NG101

  10. Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers (HTG355)

    Evidence-based recommendations on Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers.

    HealthTech guidance
    Last updated
    19 May 2021
    View recommendations

    Sections for HTG355

  11. NICE encourages further research into ultrasound-enhanced, catheter-directedthrombolysis for pulmonary embolism. Ideally this should include comparative studies against catheter-directed thrombolysis alone. Patient selection should be  documented. The dose of thrombolytic agent used and the duration of thrombolysis should be reported, together with all complications. Outcome measures should include the success of thrombolysis (complete, partial or failed) and long-term sequelae. NICE may update the guidance on publication of further evidence.

    IPG524/1 Question NICE encourages further research into ultrasound-enhanced, catheter-directedthrombolysis for pulmonary embolism....

    Research recommendation
    Published
    6 October 2015

  12. NICE encourages further research comparing ultrasound-enhanced, catheter-directed thrombolysis for deep vein thrombosis against catheter-directed thrombolysis alone. Patient selection should be documented, including the duration and extent of thrombosis. The dose of thrombolytic agent used and the duration of thrombolysis should be reported, together with all complications. Outcome measures should include the success of thrombolysis (complete, partial or failed) and long-term sequelae. NICE may update the guidance on publication of further evidence.

    IPG523/1 Question NICE encourages further research comparing ultrasound-enhanced, catheter-directed thrombolysis for deep vein...

    Research recommendation
    Published
    5 October 2015

  13. The Epidrum for aiding access to the epidural space (MIB23)

    NICE has developed a medtech innovation briefing (MIB) on the Epidrum for aiding access to the epidural space

    Medtech innovation briefing
    Published
    2 March 2015

  14. Therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) (HTG124)

    Evidence-based recommendations on therapeutic amnioinfusion for treating oligohydramnios during pregnancy (excluding labour). This involves injecting a substance similar to amniotic fluid into the space around the baby.

    HealthTech guidance
    Published
    22 November 2006
    View recommendations

    Sections for HTG124

  15. Interstitial laser therapy for breast cancer (HTG55)

    Evidence-based recommendations on interstitial laser therapy for breast cancer. This involves using laser energy to destroying the cancer cells.

    HealthTech guidance
    Published
    22 September 2004
    View recommendations

    Sections for HTG55